Micro-X Secures First Major U.S. Supply Agreement for Rover Plus Mobile Radiology System

Micro-X Ltd (ASX: MX1) has signed a Supply Agreement with a top-tier U.S. healthcare services provider for its Rover Plus mobile radiology system. The Customer operates a nationwide network of over 700 hospitals, surgical centres, and outpatient facilities, treating more than 8.5 million patients annually. The agreement follows a successful in-hospital evaluation and competitive tender process in 2024, marking Micro-X’s first supply partnership with a major U.S. healthcare organisation. Rover Plus is now included on the Customer’s approved procurement list, allowing member hospitals to purchase units without further evaluation or internal tenders.

The Supply Agreement includes standard commercial terms, covering supply schedules, warranties, and tiered pricing. CEO Kingsley Hall highlighted that this milestone demonstrates market confidence in Rover Plus and is pivotal to Micro-X’s U.S. commercial expansion. With negotiations ongoing for a second U.S. sales opportunity, the Company aims to establish itself as a leading medical imaging vendor, starting with Rover Plus and expanding toward future CT solutions.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com